Kelly Lyles, MD
Internal Medicine · Florence, SCNPI 1073585550
Payments from drug & device makers
Across 158 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$557
- AbbVie$515
- GSK$246
- Amgen$197
- Lilly USA, LLC$129
- Novartis$120
- plus $751 from 20 others
What the payments were for
- Food & beverage$2,516100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $557 |
| AbbVie | 29 | $515 |
| GSK | 15 | $246 |
| Amgen | 13 | $197 |
| Lilly USA, LLC | 9 | $129 |
| Novartis | 7 | $120 |
| Amarin Pharma, Inc. | 6 | $114 |
| Bayer | 6 | $102 |
| Dexcom, Inc. | 4 | $73 |
| Johnson & Johnson | 5 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| EMD Serono, Inc. | 1 | $36 |
| AstraZeneca | 2 | $33 |
| Abbott | 2 | $33 |
| Merck | 2 | $28 |
| Boehringer Ingelheim | 2 | $27 |
| Genentech USA, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Valeritas, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Cequr Corporation | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $9 |
How this compares
$2,516 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $109,061 |
| OzempicSemaglutide | 76 | $86,691 |
| MounjaroTirzepatide | 37 | $61,569 |
| TrulicityDulaglutide | 38 | $42,236 |
| MyrbetriqMirabegron | 42 | $35,178 |
| XareltoRivaroxaban | 16 | $25,024 |
| JardianceEmpagliflozin | 15 | $23,002 |
| Repatha SureclickEvolocumab | 13 | $18,876 |
| EntrestoSacubitril/Valsartan | 14 | $17,879 |
| FarxigaDapagliflozin Propanediol | 12 | $17,386 |
| LivaloPitavastatin Calcium | 20 | $15,131 |
| JanuviaSitagliptin Phosphate | 15 | $13,153 |
| Rosuvastatin Calcium | 483 | $11,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,976 |
| SynthroidLevothyroxine Sodium | 135 | $10,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $129 | $103,80575 claims |
| Novo NordiskOzempic | $557 | $86,69176 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $35,17842 claims |
| Johnson & JohnsonXarelto | $64 | $25,02416 claims |
| Boehringer IngelheimJardiance | $27 | $23,00215 claims |
| AbbVieSynthroid, Linzess | $515 | $18,125147 claims |
| MerckJanuvia, Belsomra | $28 | $18,05226 claims |
| NovartisEntresto | $120 | $17,87914 claims |
| AstraZenecaFarxiga | $33 | $17,38612 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $246 | $16,23529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Florence
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.